SciBase initiates collaboration with Inderes for commissioned research
07.08.2025 - 18:03:15 | prnewswire.co.ukThe main purpose of the collaboration is to:
Increase investor awareness of SciBaseHelp investors better understand SciBaseCreate a communication channel between the investors and SciBaseImprove the price formation and liquidity of SciBase's stockFor additional information, please contact:
Pia Renaudin, VD, tel. +46732069802, e-mail: pia.renaudin@scibase.com
Michael Colerus, CFO, tel. +46703413472, e-mail: Michael.colerus@scibase.com
Certified Advisor (CA):
Vator Securities
Tel: +46 8 580 065 99
Email: ca@vatorsec.se
About SciBase
SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to elevate diagnostic accuracy, ensuring proactive skin health management.
Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.
Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.
The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015. Learn more at www.scibase.com. All press-releases and financial reports can be found here : http://investors.scibase.se/en/pressreleases
About Inderes
Inderes connects investors and listed companies, with the aim of democratizing information in the financial markets. Inderes helps over 400 Nordic listed companies to better serve their shareholders. Inderes' Nordic community consists of over 70,000 active investors.
The following files are available for download:
https://mb.cision.com/Main/12371/3917413/2568363.pdf
Inderes PR
View original content:https://www.prnewswire.co.uk/news-releases/scibase-initiates-collaboration-with-inderes-for-commissioned-research-302047579.html
Hol dir jetzt den Wissensvorsprung der Aktien-Profis.
Für. Immer. Kostenlos.

